Get the Stockscreener App
6.07
6.76%
-0.44
After Hours:
6.07
Capricor Therapeutics Inc stock is traded at $6.07, with a volume of 1.88M.
It is down -6.76% in the last 24 hours and down -17.53% over the past month.
Capricor Therapeutics Inc is a clinical-stage biotechnology company focused on the development of transformative cell and exosome-based therapeutics for treating Duchenne muscular dystrophy (DMD), a rare form of muscular dystrophy which results in muscle degeneration and premature death, and other diseases with high unmet medical needs. The company's product pipeline includes CAP-1002, deramiocel an allogeneic cardiac-derived cell therapy. Deramiocel is currently advancing through Phase 3 clinical development for the treatment of Duchenne muscular dystrophy. Through its proprietary StealthXTM platform, the group uses its exosome technology to conduct preclinical research focused on vaccinology, delivering oligonucleotides, proteins, and small molecules to treat.
See More
Previous Close:
$6.51
Open:
$6.45
24h Volume:
1.88M
Relative Volume:
1.42
Market Cap:
$277.50M
Revenue:
$27.10M
Net Income/Loss:
$-24.31M
P/E Ratio:
-7.3133
EPS:
-0.83
Net Cash Flow:
$-33.33M
1W Performance:
-1.78%
1M Performance:
-17.53%
6M Performance:
-48.82%
1Y Performance:
-68.79%
1-Day Range:
$6.06
$6.4645
1-Week Range:
$6.06
$7.08
52-Week Range:
$5.68
$20.75
Capricor Therapeutics Inc Stock (CAPR) Company Profile
Name
Capricor Therapeutics Inc
Sector
Industry
Phone
(310) 358-3200
Address
10865 ROAD TO THE CURE, SAN DIEGO, CA
Compare CAPR with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
CAPR
Capricor Therapeutics Inc
|
6.07 | 297.62M | 27.10M | -24.31M | -33.33M | -0.83 |
|
VRTX
Vertex Pharmaceuticals Inc
|
426.00 | 109.11B | 11.39B | 3.64B | 3.50B | 13.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
642.25 | 68.50B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
434.07 | 60.25B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ARGX
Argen X Se Adr
|
826.28 | 50.39B | 3.06B | 1.28B | 447.35M | 19.67 |
|
INSM
Insmed Inc
|
186.23 | 40.44B | 447.02M | -1.18B | -868.57M | -6.1812 |
Capricor Therapeutics Inc Stock (CAPR) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jun-30-25 | Initiated | Alliance Global Partners | Buy |
| Jun-26-25 | Initiated | B. Riley Securities | Buy |
| May-20-25 | Initiated | Roth Capital | Buy |
| Oct-21-24 | Initiated | Piper Sandler | Overweight |
| May-17-24 | Initiated | Oppenheimer | Outperform |
| Jan-05-24 | Initiated | Cantor Fitzgerald | Overweight |
| Oct-26-22 | Initiated | Ladenburg Thalmann | Buy |
| Dec-26-18 | Downgrade | Maxim Group | Buy → Hold |
| Jan-26-18 | Reiterated | H.C. Wainwright | Buy |
| Sep-15-17 | Reiterated | H.C. Wainwright | Buy |
| Feb-13-17 | Resumed | Rodman & Renshaw | Buy |
| Jul-06-16 | Resumed | H.C. Wainwright | Buy |
| Jun-15-16 | Initiated | ROTH Capital | Buy |
View All
Capricor Therapeutics Inc Stock (CAPR) Latest News
Capricor Therapeutics (CAPR) Advances DMD Treatment with New Res - GuruFocus
Chart based analysis of Capricor Therapeutics Inc. trendsTrade Risk Report & Fast Entry High Yield Stock Tips - newser.com
Strategies to average down on Capricor Therapeutics Inc.2025 Market Outlook & Weekly Top Gainers Alerts - newser.com
What insider purchases suggest about Capricor Therapeutics Inc. (4LN2) stockJuly 2025 Setups & Stepwise Trade Signal Implementation - newser.com
Capricor (NASDAQ: CAPR) publishes Deramiocel MOA; assay supports Phase 3 DMD - Stock Titan
Smart tools for monitoring Capricor Therapeutics Inc.’s price actionJuly 2025 Retail & AI Based Buy/Sell Signal Reports - newser.com
Is Capricor Therapeutics Inc. (4LN2) stock a momentum leader2025 Earnings Surprises & Low Risk Entry Point Guides - newser.com
Will Capricor Therapeutics Inc. price bounce be sustainableQuarterly Portfolio Review & Verified Momentum Watchlists - newser.com
Why Capricor Therapeutics Inc. stock is a must watch in 2025Weekly Trend Summary & Fast Moving Trade Plans - newser.com
Will Capricor Therapeutics Inc. (4LN2) stock outperform energy sector in 2025July 2025 Earnings & Trade Opportunity Analysis - newser.com
Price momentum metrics for Capricor Therapeutics Inc. explained2025 Trading Volume Trends & Long-Term Growth Stock Strategies - newser.com
What valuation multiples suggest for Capricor Therapeutics Inc. stock2025 Institutional Moves & Consistent Growth Stock Picks - newser.com
What institutional flow reveals about Capricor Therapeutics Inc.July 2025 Catalysts & Verified Momentum Stock Ideas - newser.com
Will Capricor Therapeutics Inc. stock benefit from upcoming earnings reportsMarket Volume Report & Free Low Drawdown Momentum Trade Ideas - newser.com
Capricor Therapeutics Inc.’s volatility index tracking explainedGap Up & Daily Growth Stock Tips - newser.com
Chart overlay techniques for tracking Capricor Therapeutics Inc.Weekly Trend Summary & Community Supported Trade Ideas - newser.com
Will Capricor Therapeutics Inc. (4LN2) stock see insider accumulationGlobal Markets & AI Forecast for Swing Trade Picks - newser.com
Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against Capricor Therapeutics, Inc. (CAPR) and Encourages Investors to Learn More About the Investigation - ACCESS Newswire
Is it too late to sell Capricor Therapeutics Inc.Market Movers & Community Driven Trade Alerts - newser.com
HBK Sorce Advisory LLC Increases Stake in Capricor Therapeutics, Inc. $CAPR - MarketBeat
Capricor Therapeutics Inc. stock trend outlook and recovery pathJuly 2025 WrapUp & Real-Time Volume Trigger Notifications - newser.com
Capricor Therapeutics to Present Third Quarter 2025 Financial Results and Recent Corporate Update on November 10 - The Manila Times
Capricor Therapeutics to Announce Third Quarter 2025 Financial Results on November 10, 2025 - Quiver Quantitative
We're Hopeful That Capricor Therapeutics (NASDAQ:CAPR) Will Use Its Cash Wisely - Yahoo Finance
What technical charts say about Capricor Therapeutics Inc. stockEarnings Growth Summary & AI Driven Stock Movement Reports - newser.com
How big funds are accumulating Capricor Therapeutics Inc. (4LN2) stockPortfolio Performance Report & Free Fast Gain Swing Trade Alerts - newser.com
Bronstein, Gewirtz & Grossman, LLC Initiates an Investigation into Allegations Against Capricor Therapeutics, Inc. (CAPR) And Encourages Investors to Reach Out - ACCESS Newswire
Capricor (CAPR) Moves 12.0% Higher: Will This Strength Last? - Yahoo Finance
Capricor Therapeutics Inc Stock (CAPR) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.64%
0.35%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):